Cable Hill Partners’s Acceleron Pharma XLRN Stock Holding History

Cable Hill Partners’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-49	Closed	-$2K	–	787
2019 Q1	$2K	Hold	49	–	–	﹤0.01%	776
2018 Q4	$2K	Hold	49	–	–	﹤0.01%	738
2018 Q3	$3K	Sell	49 -9	-16%	-$442	﹤0.01%	684
2018 Q2	$3K	Hold	58	–	–	﹤0.01%	804
2018 Q1	$2K	Sell	58 -93	-62%	-$3.95K	﹤0.01%	843
2017 Q4	$6K	Hold	151	–	–	﹤0.01%	710
2017 Q3	$6K	Sell	151 -3	-2%	-$104	﹤0.01%	731
2017 Q2	$5K	Hold	154	–	–	﹤0.01%	574
2017 Q1	$4K	Sell	154 -10	-6%	-$264	﹤0.01%	602
2016 Q4	$4K	Buy	164 +36	+28%	+$1.14K	﹤0.01%	598
2016 Q3	$4K	Sell	128 -8	-6%	-$265	﹤0.01%	638
2016 Q2	$5K	Hold	136	–	–	﹤0.01%	516
2016 Q1	$4K	Buy	136 +77	+131%	+$2.24K	﹤0.01%	529
2015 Q4	$3K	Buy	+59	New	+$2.12K	﹤0.01%	566

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Cable Hill Partners's XLRN Position: Q2 2019 in Review

Cable Hill Partners sold out of Acceleron Pharma (XLRN) in Q2 2019, closing a stake of 49 shares — an estimated $2K sold.

Cable Hill Partners first reported a position in XLRN in Q4 2015 and held it in 14 quarters. The position peaked at $6K in Q4 2017. 166 funds tracked by Wall St. Rank hold XLRN as of Q2 2019.

Cable Hill Partners reported no remaining Acceleron Pharma position as of Q2 2019 after selling out during the quarter.
Cable Hill Partners sold 49 Acceleron Pharma shares in Q2 2019, an estimated $2K.
Cable Hill Partners first reported a position in Acceleron Pharma in Q4 2015 and held it in 14 quarters.
Cable Hill Partners's Acceleron Pharma position peaked at $6K in Q4 2017.
166 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.